Fundraising Fox

EpimAb Biotherapeutics

Shanghai, CN · 5 known investors

Epimab Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of bispecific antibodies using proprietary technology platforms including FIT-Ig® and MAT-Fab. The company is advancing a pipeline of novel candidates targeting unmet clinical needs, with a focus on oncology applications.

BiotechHealthtechMedical Devices

Founders & leadership

WC
Wu ChenbingFounder/Expert

Investors · 5

Decheng CapitalMenlo Park
ShangBay Capital LLCPalo Alto
TCG LabsSan Francisco
3E Bioventures CapitalreportedPalo Alto
Sherpa Healthcare PartnersreportedGrand Cayman

In the news

Candid Therapeutics Raises $370M in Fundingfinsmes.com · Sep 2024Asher raises $55M; Roche's Huntington's trial; EpimAb bags $120Mdelveinsight.com · Mar 2021Chinese biopharma firm EpimAb bags $74m Series Bdealstreetasia.com · Jun 2019EpimAb Biotherapeutics Raises $74M in Series B Financing - BioSpacebiospace.com · Jun 2019EpimAb Biotherapeutics Raises $25M In Series A Financing From International Consortium To Advance Pipeline Of Novel Bispecific Antibodies - BioSpacebiospace.com · Apr 2017

Frequently asked questions

What does EpimAb Biotherapeutics do?
Epimab Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of bispecific antibodies using proprietary technology platforms including FIT-Ig® and MAT-Fab. The company is advancing a pipeline of novel candidates targeting unmet clinical needs, with a focus on oncology applications.
Who founded EpimAb Biotherapeutics?
EpimAb Biotherapeutics was founded by Wu Chenbing.
Who are EpimAb Biotherapeutics's investors?
EpimAb Biotherapeutics's investors include Decheng Capital, ShangBay Capital LLC, TCG Labs, 3E Bioventures Capital, Sherpa Healthcare Partners.
Where is EpimAb Biotherapeutics headquartered?
EpimAb Biotherapeutics is headquartered in Shanghai, CN.